Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Prednisolone Trial in Children Younger Than 4 Years

Phase 3

Completed

Conditions: Nephrotic Syndrome

Interventions: Drug: Prednisolone

First Posted Date: 2017-05-05

Last Posted Date: 2024-01-30

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 170

Registration Number: NCT03141970

Locations: 🇺🇸
Levine's Children/Carolinas HealthCare System, Charlotte, North Carolina, United States
🇺🇸
Cedars-Sinai Medical Center, Pediatric IBD & Pediatric Nephrology, Los Angeles, California, United States
🇺🇸
Stanford University Medical Center, Department of Pediatrics, Division of Nephrology, Stanford, California, United States

and more 2 locations

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Early Phase 1

Withdrawn

Conditions: Severe Alcoholic Hepatitis

Interventions: Drug: GS-4997
Drug: Prednisolone
Device: HepQuant SHUNT Test
Drug: Placebo

First Posted Date: 2017-03-23

Last Posted Date: 2021-08-30

Lead Sponsor: HepQuant, LLC

Registration Number: NCT03087968

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States

and more 9 locations

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

Phase 2

Conditions: Cerebral Radiation Necrosis

Interventions: Drug: Methylprednisolone (Steroid Hormone)
Drug: Monosialoganglioside Ganglioside
Drug: Prednisolone

First Posted Date: 2017-03-01

Last Posted Date: 2017-03-01

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 28

Registration Number: NCT03067753

Locations: 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

First Posted Date: 2017-01-02

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 475

Registration Number: NCT03007147

Locations: 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 224 locations

Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

Phase 4

Terminated

Conditions: Psychotic Disorder NOS
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder

Interventions: Drug: Placebo Oral Tablet
Drug: Prednisolone

First Posted Date: 2016-10-31

Last Posted Date: 2019-06-24

Lead Sponsor: UMC Utrecht

Target Recruit Count: 42

Registration Number: NCT02949232

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇩🇰
University Aarhus, Risskov, Denmark
🇧🇪
ZNA, Antwerp, Belgium

and more 1 locations

Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil
Drug: Azathioprine
Drug: Prednisolone

First Posted Date: 2016-10-31

Last Posted Date: 2017-03-03

Lead Sponsor: Genovate Biotechnology Co., Ltd.,

Target Recruit Count: 32

Registration Number: NCT02949349

Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants

Phase 2

Terminated

Conditions: Opioid Dependence
Cocaine Dependence

Interventions: Drug: Placebo (for Prednisolone)
Drug: Prednisolone

First Posted Date: 2016-10-17

Last Posted Date: 2019-05-23

Lead Sponsor: Prof. Dominique de Quervain, MD

Target Recruit Count: 4

Registration Number: NCT02935101

Locations: 🇨🇭
Psychiatric Hospital University of Basel, Basel, Switzerland

Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy

Phase 3

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Leflunomide
Drug: Hydroxychloroquine
Drug: Prednisolone
Drug: Folic Acid
Drug: Sulfasalazine

First Posted Date: 2016-10-12

Last Posted Date: 2021-07-27

Lead Sponsor: Jawaharlal Institute of Postgraduate Medical Education & Research

Target Recruit Count: 136

Registration Number: NCT02930343

Locations: 🇮🇳
Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India

Acute Unilateral Vestibulopathy and Corticosteroid Treatment

Phase 4

Terminated

Conditions: Vestibular Diseases
Vestibular Neuronitis

Interventions: Drug: Placebo
Drug: Betamethasone
Drug: Prednisolone

First Posted Date: 2016-09-23

Last Posted Date: 2021-09-10

Lead Sponsor: Lund University

Target Recruit Count: 78

Registration Number: NCT02912182

Locations: 🇸🇪
Dept OtoRhinoLaryngology, Helsingborg, Sweden
🇸🇪
Dept. OtoRhinoLaryngology Head and Neck Surgery, Skane University Hospital, Lund, Sweden
🇸🇪
Dept. Otorhinolaryngology, Kristianstad, Sweden

Alipogene Tiparvovec for the Treatment of LPLD Patients

Phase 2

Withdrawn

Conditions: LPL Deficiency

Interventions: Drug: alipogene tiparvovec
Drug: Prednisolone
Drug: Cyclosporins
Drug: Mycophenolate mofetil

First Posted Date: 2016-09-19

Last Posted Date: 2017-08-17

Lead Sponsor: UniQure Biopharma B.V.

Registration Number: NCT02904772

Locations: 🇺🇸
Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics, Philadelphia, Pennsylvania, United States
🇨🇦
Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy